Clinical trials: Acute Gastrointestinal Graft-versus-host Disease
Cholecystitis, Acute, Cholecystitis, Chronic
Study of Pain Perception Between Males and Females Following Laparoscopic Cholecystectomy
This study looks at the differences in inflammatory mediators in gallbladder tissue between males and females and the possibility that these differences contribute to a higher perception of post-operative pain in females…
- Trial name
- NCT00575276
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
GVHD,Acute, Ulcerative Colitis
Analysis of Intestinal Defensin Expression in Acute GVHD
This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute GVHD. The expression will be compared to intestinal expression of defensins in patients with colitis and patients…
- Conditions
- GVHD,Acute, Ulcerative Colitis, Morbus Crohn
- Trial name
- NCT04522843
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University of Freiburg
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
MaaT013 is still in clinical development phase and is not approved yet for marketing in any region. During the development program, MaaT Pharma has undertaken initial development with closely related product candidates, leading…
- Trial name
- ATLAS (NCT04768907)
- Testing
- MaaT013
- Where
- 46 sites in Austria, Belgium and 6 more
- Sponsor
- MaaT Pharma
Acute Graft-Versus-Host Disease, GIGVHD
A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
The objectives of this trial were to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in participants with acute graft-versus-host disease (GVHD) of the lower…
- Trial name
- GIGVHD (NCT02245412)
- Testing
- ALXN1007 10 mg/kg once weekly, ALXN1007 20 mg/kg once weekly, ALXN1007 20 mg/kg twice weekly
- Where
- 12 sites in United States, France
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.